Pharscin Pharma(002907)

Search documents
A股午评:创业板指高开高走半日涨1.16% 无人驾驶概念掀涨停潮
news flash· 2025-05-29 03:33
Market Overview - The three major A-share indices rose collectively in the morning session, with the Shanghai Composite Index up 0.72%, the Shenzhen Component Index up 1.12%, and the ChiNext Index up 1.16% [1] - The total market turnover reached 759.4 billion yuan, an increase of 91.6 billion yuan compared to the previous day, with over 4,400 stocks rising [1] Sector Performance - The leading sectors included autonomous driving, innovative pharmaceuticals, and cross-border payments, while precious metals and food sectors saw declines [2] - Notable stocks in the autonomous driving sector included Yunnei Power and Tongda Electric, both achieving four consecutive trading limit increases [2] - The innovative pharmaceutical sector also performed well, with stocks like Ruizhi Pharmaceutical and Shutaishen hitting trading limits [2] Notable Stocks and Trends - The stock of Shangwei Co. achieved six consecutive trading limit increases, indicating strong investor interest [4] - Stocks such as Yunnei Power and Tongda Electric have shown significant momentum with four consecutive trading limit increases [5] - The innovative pharmaceutical company Shutaishen reported promising clinical trial results for its STSA-1002 injection, showing a significant reduction in mortality rates compared to the control group [10] Strategic Developments - A strategic cooperation framework agreement was signed between Xiaoma Zhixing and Guangzhou Public Transport Group to collaborate in the fields of autonomous vehicles and logistics services [11] - The market is also reacting to legislative developments regarding stablecoins in the U.S. and Hong Kong, which may impact the cross-border payment sector [13]
创新药概念爆发,睿智医药、舒泰神20%涨停,华森制药3连板
Zheng Quan Shi Bao Wang· 2025-05-29 02:39
公司同时提示,本次STSA-1002注射液(急性呼吸窘迫综合征适应症)仅取得顶线数据的初步统计分析 结果,STSA-1002注射液项目在该适应症方向的完整有效性、安全性结果将以未来最终临床总结报告为 准。本次STSA-1002注射液(急性呼吸窘迫综合征适应症)获得Ib/II期临床试验研究初步结果不会对公 司当前业绩产生重大影响。后续临床试验阶段是否顺利、能否获得生产批件、具备上市资格尚存在诸多 不确定。 创新药概念29日盘中强势拉升,截至发稿,睿智医药(300149)、舒泰神(300204)20%涨停,键凯科 技、益方生物涨超12%,华森制药(002907)涨停斩获3连板,博瑞医药涨超8%。 行业方面,当地时间2025年5月30日至6月3日,2025年美国临床肿瘤学会(ASCO)年会将在美国芝加 哥举行。据悉,ASCO年会作为全球规模最大、学术水平最高、最具权威性的临床肿瘤学会议之一,见 证了中国肿瘤学研究的发展。目前,中国药企入选的临床研究逐年增多,展示了其在新药研发方面的活 跃度和竞争力,2025年中国学者入选会议的研究达到70余项,其中恒瑞医药(600276)、信达生物、荣 昌生物、泽璟制药、正大天晴、 ...
华森制药连收3个涨停板
Zheng Quan Shi Bao Wang· 2025-05-29 02:16
Group 1 - The stock of Huason Pharmaceutical has reached a limit-up, marking three consecutive limit-up days, with a current price of 18.80 yuan and a turnover rate of 8.06% [2] - During the consecutive limit-up period, the stock has increased by 33.05%, with a cumulative turnover rate of 22.87% [2] - The latest total market capitalization of the A-shares is 78.51 billion yuan, with a circulating market capitalization of 58.07 billion yuan [2] Group 2 - The stock has appeared on the Dragon and Tiger List due to a cumulative deviation of 20% in its price over three trading days, with institutional net purchases amounting to 3.3683 million yuan and a total net sale by the Shenzhen Stock Connect of 32.3933 million yuan [2] - The company reported a total operating revenue of 239 million yuan for the first quarter, representing a year-on-year growth of 4.62%, and a net profit of 40 million yuan, with a slight increase of 0.01% year-on-year [2] Group 3 - Recent trading data shows significant fluctuations in daily price changes and net inflows of main funds, with the highest daily increase recorded at 9.97% on May 28, 2025, and a net inflow of 59.923 million yuan [2] - The stock has experienced varying turnover rates, with the highest at 11.94% on the same day, indicating active trading [2]
华森制药: 股票交易异常波动公告
Zheng Quan Zhi Xing· 2025-05-28 09:22
Group 1 - The stock of Chongqing Huason Pharmaceutical Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative price increase of 21.52% over two consecutive trading days on May 27 and May 28, 2025 [1][2] - The company's board confirmed that there were no undisclosed significant matters that could have impacted the stock price, and the operational situation remains normal without any major changes [1][2] - The controlling shareholder and actual controller did not engage in buying or selling the company's stock during the period of abnormal trading [2] Group 2 - The board of directors confirmed that there are no undisclosed matters that should be disclosed according to the Shenzhen Stock Exchange's regulations [2] - The company emphasized that it has not violated any information disclosure regulations and reminded investors to pay attention to potential risks as outlined in the 2024 annual report [2]
华森制药(002907) - 股票交易异常波动公告
2025-05-28 09:02
股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整, 没有虚假记载、误导性陈述或重大遗漏。 一、股票交易异常波动情况的说明 重庆华森制药股份有限公司(以下简称"公司")股票(证券简称:华森制 药,证券代码:002907)于 2025 年 5 月 27 日、5 月 28 日连续 2 个交易日内收 盘价涨幅偏离值累计达到 21.52%。根据《深圳证券交易所交易规则》的有关规 定,属于股票交易异常波动情况。 证券代码:002907 证券简称:华森制药 公告编号:2025-048 重庆华森制药股份有限公司 (五)经核查,控股股东、实际控制人在股票异常波动期间不存在买卖公司 股票的情形。 三、是否存在应披露而未披露信息的说明 本公司董事会确认,本公司目前没有任何根据深交所《股票上市规则》等有 关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、意向、协议等; 董事会也未获悉本公司有根据深交所《股票上市规则》等有关规定应予以披露而 未披露的、对本公司股票及其衍生品种交易价格产生较大影响的信息;公司前期 披露的信息不存在需要更正、补充之处。 四、上市公司认为必要的风险提示 二、对重要问题的 ...
华森制药(002907) - 关于公司收到药品再注册批准通知书的公告
2025-05-28 09:00
证券代码:002907 证券简称:华森制药 公告编号:2025-047 重庆华森制药股份有限公司 一、《药品再注册批准通知书》主要信息 增生、甲状腺结节、子宫肌瘤等疗效突出,可软化包块、缩小囊肿、减轻症状。 平消片被列入《肿瘤中医诊疗指南》《中医外科常见病诊疗指南》《中成药临床 应用指南·消化疾病分册》《中成药临床应用指南·呼吸系统疾病分册》《临床 路径治疗药物释义肿瘤疾病分册》《中医临床诊疗指南释义》《国家基本药物临 床应用指南(中成药)》等多项临床指南或专家共识。 三、对公司的影响 本次公司获得平消片的《药品再注册批准通知书》将确保该药品的正常生产 和销售,公司将严格按照要求开展相关工作,控制产品质量,持续为市场提供 高品质的产品。 关于公司收到药品再注册批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整, 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司(以下简称"公司")于近日收到重庆市药品监 督管理局(以下简称"市药监局")核准签发的关于公司药品平消片的《药品再 注册批准通知书》。现将相关情况公告如下: | 药 | 品 | | 通 | 用 | | 名 称:平消片 ...
华森制药(002907) - 2024年度暨2025年一季度业绩网上说明会投资者关系活动记录表
2025-05-28 08:50
Group 1: Company Performance and Financials - In 2024, the company achieved a revenue of 775 million CNY, a year-on-year increase of 12.04% [4] - In Q1 2025, the company reported a revenue of 239 million CNY, a year-on-year increase of 4.62%, with a slowdown attributed to reduced market demand for key products [4] - The five key traditional Chinese medicine products saw a slight revenue increase of 0.93% in Q1 2025, with notable growth in specific products like Liuwei Anshen Capsules (32.10% increase) and Tongxie Ning Granules (80.24% increase) [4] Group 2: Research and Development - The company has integrated its R&D pipeline with Chengdu Aorui Pharmaceutical, resulting in 7 independent Class 1 innovative drug projects targeting various cancers and autoimmune diseases [3] - The lead project, ORIC-1940, is in clinical phase Ia/Ib and is expected to be the first Class 1 innovative drug for secondary hemophagocytic lymphohistiocytosis in China [3] - The company has established multiple R&D platforms and has applied for 35 patents, including 17 PCT patents [3] Group 3: Product Development and Market Strategy - The company has 4 self-researched special medical foods projects, with the TY005 project receiving regulatory approval, marking a breakthrough in the special medical food sector [4] - The five key traditional Chinese medicine products are in a growth phase, with plans for further market expansion and academic promotion to enhance market access [5][6] - The company aims to launch at least 3 new drug varieties annually over the next five years, alongside special medical foods and health consumer products [12] Group 4: International Expansion - The company successfully passed the FDA's cGMP inspection for its fifth production base, facilitating international quality standards [7] - Key traditional Chinese medicine products have received registration approvals for sale in Singapore, marking a significant milestone for international market entry [7] Group 5: Corporate Governance and Investor Relations - The company emphasizes transparent communication with investors, regularly hosting performance briefings and investor engagement activities [8] - Independent directors play a crucial role in overseeing the accuracy and completeness of financial reports, ensuring compliance with regulatory standards [9] Group 6: Future Strategic Focus - The company will focus on high-quality development, leveraging talent and innovation to enhance its competitive edge in the pharmaceutical industry [10] - Plans include expanding into oncology and autoimmune disease research, while also enhancing the efficiency of generic drug development [11]
幽门螺杆菌概念涨2.18%,主力资金净流入32股
Zheng Quan Shi Bao Wang· 2025-05-27 10:23
Core Insights - The Helicobacter pylori concept stock increased by 2.18%, ranking 8th among concept sectors in terms of growth [2] - A total of 61 stocks within this sector saw an increase, with notable performers including Keta Bio (科拓生物) reaching a 20% limit up, and other stocks like Jiaotong University Anli (交大昂立) and Junyao Health (均瑶健康) also hitting the limit up [2][3] Market Performance - The Helicobacter pylori concept sector attracted a net inflow of 367 million yuan, with 32 stocks receiving net inflows [3][4] - Jiaotong University Anli led the net inflow with 191 million yuan, followed by Keta Bio with 90.21 million yuan and Kelun Pharmaceutical (科伦药业) with 69.54 million yuan [3][4] Stock Performance - The stocks with the highest net inflow ratios included *ST Sailong (88.77%), Junyao Health (75.70%), and Huason Pharmaceutical (华森制药) (50.71%) [4] - The top stocks by net inflow and their respective performance included: - Jiaotong University Anli: +10.01%, net inflow of 190.68 million yuan [4] - Keta Bio: +19.99%, net inflow of 90.21 million yuan [4] - Huason Pharmaceutical: +9.98%, net inflow of 68.11 million yuan [4]
突然拉升!涨停!
Zhong Guo Ji Jin Bao· 2025-05-27 02:42
Group 1: Market Overview - The People's Bank of China conducted a 7-day reverse repo operation of 448 billion yuan at an interest rate of 1.40% on May 27, with 357 billion yuan of reverse repos maturing on the same day [1][5] - A-shares opened slightly lower but showed signs of recovery, with the Shanghai Composite Index fluctuating and turning positive [5][6] - The consumer sector, particularly food and beverage, showed initial strength, while the pharmaceutical sector rebounded [6][12] Group 2: Pharmaceutical Sector - The pharmaceutical and biotechnology sector experienced a partial rebound, with notable stocks such as Longshen Rongfa hitting the daily limit, and Sanofi Guojian rising over 10% [12][13] - Hong Kong pharmaceutical stocks also saw gains, with notable increases in companies like CSPC Pharmaceutical and China Biologic Products [8][14] Group 3: Nuclear Power Sector - The nuclear power sector continued its recent strong performance, with stocks like Shangwei Co. and Rongfa Nuclear Power achieving multiple consecutive gains [9][11] - Recent reports indicate a positive outlook for the controllable nuclear fusion industry, driven by favorable policies and increased financing [11] Group 4: Food and Beverage Sector - The food and beverage sector saw a surge, with stocks like Kuaijishan and Junyao Health achieving significant gains [15][16] - Kuaijishan's market capitalization surpassed that of Guyue Longshan, establishing it as a leading player in the yellow wine industry [15] Group 5: Cultivated Diamond Sector - The cultivated diamond sector experienced a sharp rise, with stocks like Huanghe Xuanfeng and Huifeng Diamond hitting the daily limit [17][18] - Huanghe Xuanfeng announced a partnership to establish a joint venture focused on advanced semiconductor materials, which is expected to enhance the development of high-performance thermal materials [19]
华森制药(002907) - 关于举行2024年度暨2025年一季度业绩网上说明会的通知
2025-05-26 08:15
重庆华森制药股份有限公司 关于举行2024年度暨2025年一季度业绩网上说明会的通知 证券代码:002907 证券简称:华森制药 公告编号:2025-046 届时,公司董事长、独立董事、总经理、财务总监、董事会秘书等主要领 导将出席本次业绩网上说明会(如有特殊情况,参与人员会有调整)。 三、投资者参加方式 投资者可登录"路演中"(http://www.roadshowchina.cn/)预约参与本 次2024年度暨2025年一季度业绩网上说明会。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整, 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司(以下简称 "公司")《2024年年度报告》全 文及其摘要和《2025年一季度报告》已于2025年4月25日披露,为便于广大投资 者更深入、全面地了解公司经营情况和发展战略,公司拟召开"2024年度暨 2025年一季度业绩说明会"。具体情况如下: 一、会议时间、地点 业绩说明会将于2025年5月28日(星期三)15:00~16:00通过网络会议的形 式在"路演中"平台举行。 二、参加人员 四、公开征集问题 为充分尊重投资者,广泛听取投资者的意见和 ...